Prelude Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Prelude Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$190K	Sell	19,390 -12,250	-39%	-$111K	0.01%	999
2026 Q1	$268K	Buy	+31,640	New	+$302K	0.02%	760
2024 Q2	–	Sell	-44,300	Closed	-$403K	–	1411
2024 Q1	$403K	Buy	+44,300	New	+$314K	0.02%	735
2020 Q4	–	Sell	-200	Closed	-$2K	–	1777
2020 Q3	$2K	Buy	+200	New	+$1.66K	﹤0.01%	1675
2020 Q1	–	Sell	-56,164	Closed	-$222K	–	1861
2019 Q4	$222K	Buy	+56,164	New	+$195K	0.01%	826

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's OCUL Position: Q2 2026 in Review

Prelude Capital Management reduced its Ocular Therapeutix (OCUL) stake by 39% in Q2 2026, selling an estimated $111K and leaving 19,390 shares worth $190K. The position accounts for 0.01% of the portfolio, ranked #999.

Prelude Capital Management first reported a position in OCUL in Q4 2019 and has held it in 5 quarters since. The position peaked at $403K in Q1 2024. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Prelude Capital Management held 19,390 shares of Ocular Therapeutix worth $190K as of Q2 2026.
Prelude Capital Management sold 12,250 Ocular Therapeutix shares in Q2 2026, an estimated $111K.
Ocular Therapeutix made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #999 holding.
Prelude Capital Management first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 5 quarters since.
Prelude Capital Management's Ocular Therapeutix position peaked at $403K in Q1 2024.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.